ID

41238

Description

A Study of DCDT2980S in Combination With MabThera/Rituxan or DCDS4501A in Combination With MabThera/Rituxan and Evaluation of Combination DCDS4501A and Obinutuzumab in Patients With Non-Hodgkin's Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01691898

Link

https://clinicaltrials.gov/show/NCT01691898

Keywords

Versions (1)
  1. 7/22/20 7/22/20 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

July 22, 2020

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

  • Newest
  • Oldest
  • Popular
  • Newest
    • Newest
    • Oldest
    • Popular

No comments

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Lymphoma, B-Cell, Lymphoma, Follicular NCT01691898

English

Eligibility Lymphoma, B-Cell, Lymphoma, Follicular NCT01691898

1 forms  
Inclusion Criteria
Description

Inclusion Criteria

Alias
UMLS CUI
C1512693
eastern cooperative oncology group (ecog) performance status of 0, 1, or 2
Description

ECOG performance status

Data type

boolean

Alias
UMLS CUI [1]
C1520224
life expectancy of at least 12 weeks
Description

Life Expectancy

Data type

boolean

Alias
UMLS CUI [1]
C0023671
history of histologically documented relapsed or refractory grades 1-3a follicular lymphoma, or relapsed or refractory diffuse large b-cell lymphoma
Description

Recurrent Follicular Lymphoma Ann Arbor lymphoma staging system | Refractory Follicular Lymphoma Ann Arbor lymphoma staging system | Diffuse large B-cell lymphoma recurrent | Diffuse large B-cell lymphoma refractory

Data type

boolean

Alias
UMLS CUI [1,1]
C1335701
UMLS CUI [1,2]
C0432516
UMLS CUI [2,1]
C1335723
UMLS CUI [2,2]
C0432516
UMLS CUI [3]
C0855111
UMLS CUI [4]
C0855112
availability of an archival or freshly biopsied tumor tissue sample must be confirmed for study enrollment
Description

Availability of Tumor tissue sample

Data type

boolean

Alias
UMLS CUI [1,1]
C0470187
UMLS CUI [1,2]
C0475358
have a clinical indication for treatment as determined by the investigator
Description

Indication Therapeutic procedure

Data type

boolean

Alias
UMLS CUI [1,1]
C3146298
UMLS CUI [1,2]
C0087111
must have at least one bi-dimensionally measurable lesion (>1.5 cm in its largest dimension by ct scan or mri)
Description

Measurable Disease 2-Dimensional Quantity | Lesion size, largest dimension CT scan | Lesion size, largest dimension MRI

Data type

boolean

Alias
UMLS CUI [1,1]
C1513041
UMLS CUI [1,2]
C1705052
UMLS CUI [1,3]
C1265611
UMLS CUI [2,1]
C1275593
UMLS CUI [2,2]
C0040405
UMLS CUI [3,1]
C1275593
UMLS CUI [3,2]
C0024485
Exclusion Criteria
Description

Exclusion Criteria

Alias
UMLS CUI
C0680251
prior use of any monoclonal antibody, radioimmuno-conjugate or antibody drug conjugate within 4 weeks before study start
Description

Monoclonal Antibodies | Other Coding | Antibody conjugate

Data type

boolean

Alias
UMLS CUI [1]
C0003250
UMLS CUI [2]
C3846158
UMLS CUI [3]
C0598658
treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational anti-cancer agent within 2 weeks prior study start
Description

Therapeutic radiology procedure | Chemotherapy | Immunotherapy | Therapeutic immunosuppression | Antineoplastic Agents Investigational

Data type

boolean

Alias
UMLS CUI [1]
C1522449
UMLS CUI [2]
C0392920
UMLS CUI [3]
C0021083
UMLS CUI [4]
C0021079
UMLS CUI [5,1]
C0003392
UMLS CUI [5,2]
C1517586
adverse events except for sensory neuropathy from any previous treatments must be resolved or stabilized to grade </=2 prior study start
Description

Adverse event Due to Prior Therapy | Exception Sensory neuropathy | Requirement Recovery CTCAE Grades

Data type

boolean

Alias
UMLS CUI [1,1]
C0877248
UMLS CUI [1,2]
C0678226
UMLS CUI [1,3]
C1514463
UMLS CUI [2,1]
C1705847
UMLS CUI [2,2]
C0151313
UMLS CUI [3,1]
C1514873
UMLS CUI [3,2]
C2004454
UMLS CUI [3,3]
C1516728
completion of autologous stem cell transplant within 100 days prior study start
Description

Autologous hematopoietic stem cell transplant Completion

Data type

boolean

Alias
UMLS CUI [1,1]
C2193200
UMLS CUI [1,2]
C0205197
prior allogeneic stem cell transplant
Description

Allogeneic Stem Cell Transplantation

Data type

boolean

Alias
UMLS CUI [1]
C2242529
eligibility for autologous sct (patients with relapsed or refractory dlbcl)
Description

Patients Eligible Autologous hematopoietic stem cell transplant | Diffuse large B-cell lymphoma recurrent | Diffuse large B-cell lymphoma refractory

Data type

boolean

Alias
UMLS CUI [1,1]
C0030705
UMLS CUI [1,2]
C1548635
UMLS CUI [1,3]
C2193200
UMLS CUI [2]
C0855111
UMLS CUI [3]
C0855112
history of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
Description

Allergic Reaction Severe Monoclonal Antibody Therapy | Anaphylaxis Severe Monoclonal Antibody Therapy | Allergic Reaction Recombinant Fusion Proteins Antibody Related | Anaphylaxis Recombinant Fusion Proteins Antibody Related

Data type

boolean

Alias
UMLS CUI [1,1]
C1527304
UMLS CUI [1,2]
C0205082
UMLS CUI [1,3]
C0279694
UMLS CUI [2,1]
C0002792
UMLS CUI [2,2]
C0205082
UMLS CUI [2,3]
C0279694
UMLS CUI [3,1]
C1527304
UMLS CUI [3,2]
C0034857
UMLS CUI [3,3]
C0003241
UMLS CUI [3,4]
C0439849
UMLS CUI [4,1]
C0002792
UMLS CUI [4,2]
C0034857
UMLS CUI [4,3]
C0003241
UMLS CUI [4,4]
C0439849
history of other malignancy that could affect compliance with the protocol or interpretation of results
Description

Cancer Other Affecting Protocol Compliance | Cancer Other Affecting Interpretation Research results

Data type

boolean

Alias
UMLS CUI [1,1]
C1707251
UMLS CUI [1,2]
C0392760
UMLS CUI [1,3]
C0525058
UMLS CUI [2,1]
C1707251
UMLS CUI [2,2]
C0392760
UMLS CUI [2,3]
C0459471
UMLS CUI [2,4]
C0683954
current or past history of cns lymphoma
Description

Primary central nervous system lymphoma

Data type

boolean

Alias
UMLS CUI [1]
C0280803
current grade > 1 peripheral neuropathy
Description

Peripheral Neuropathy CTCAE Grades

Data type

boolean

Alias
UMLS CUI [1,1]
C0031117
UMLS CUI [1,2]
C1516728
Back to the top of the page

Similar models

Eligibility Lymphoma, B-Cell, Lymphoma, Follicular NCT01691898

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
C1512693 (UMLS CUI)
ECOG performance status
Item
eastern cooperative oncology group (ecog) performance status of 0, 1, or 2
boolean
C1520224 (UMLS CUI [1])
Life Expectancy
Item
life expectancy of at least 12 weeks
boolean
C0023671 (UMLS CUI [1])
Recurrent Follicular Lymphoma Ann Arbor lymphoma staging system | Refractory Follicular Lymphoma Ann Arbor lymphoma staging system | Diffuse large B-cell lymphoma recurrent | Diffuse large B-cell lymphoma refractory
Item
history of histologically documented relapsed or refractory grades 1-3a follicular lymphoma, or relapsed or refractory diffuse large b-cell lymphoma
boolean
C1335701 (UMLS CUI [1,1])
C0432516 (UMLS CUI [1,2])
C1335723 (UMLS CUI [2,1])
C0432516 (UMLS CUI [2,2])
C0855111 (UMLS CUI [3])
C0855112 (UMLS CUI [4])
Availability of Tumor tissue sample
Item
availability of an archival or freshly biopsied tumor tissue sample must be confirmed for study enrollment
boolean
C0470187 (UMLS CUI [1,1])
C0475358 (UMLS CUI [1,2])
Indication Therapeutic procedure
Item
have a clinical indication for treatment as determined by the investigator
boolean
C3146298 (UMLS CUI [1,1])
C0087111 (UMLS CUI [1,2])
Measurable Disease 2-Dimensional Quantity | Lesion size, largest dimension CT scan | Lesion size, largest dimension MRI
Item
must have at least one bi-dimensionally measurable lesion (>1.5 cm in its largest dimension by ct scan or mri)
boolean
C1513041 (UMLS CUI [1,1])
C1705052 (UMLS CUI [1,2])
C1265611 (UMLS CUI [1,3])
C1275593 (UMLS CUI [2,1])
C0040405 (UMLS CUI [2,2])
C1275593 (UMLS CUI [3,1])
C0024485 (UMLS CUI [3,2])
Item Group
C0680251 (UMLS CUI)
Monoclonal Antibodies | Other Coding | Antibody conjugate
Item
prior use of any monoclonal antibody, radioimmuno-conjugate or antibody drug conjugate within 4 weeks before study start
boolean
C0003250 (UMLS CUI [1])
C3846158 (UMLS CUI [2])
C0598658 (UMLS CUI [3])
Therapeutic radiology procedure | Chemotherapy | Immunotherapy | Therapeutic immunosuppression | Antineoplastic Agents Investigational
Item
treatment with radiotherapy, chemotherapy, immunotherapy, immunosuppressive therapy, or any investigational anti-cancer agent within 2 weeks prior study start
boolean
C1522449 (UMLS CUI [1])
C0392920 (UMLS CUI [2])
C0021083 (UMLS CUI [3])
C0021079 (UMLS CUI [4])
C0003392 (UMLS CUI [5,1])
C1517586 (UMLS CUI [5,2])
Adverse event Due to Prior Therapy | Exception Sensory neuropathy | Requirement Recovery CTCAE Grades
Item
adverse events except for sensory neuropathy from any previous treatments must be resolved or stabilized to grade </=2 prior study start
boolean
C0877248 (UMLS CUI [1,1])
C0678226 (UMLS CUI [1,2])
C1514463 (UMLS CUI [1,3])
C1705847 (UMLS CUI [2,1])
C0151313 (UMLS CUI [2,2])
C1514873 (UMLS CUI [3,1])
C2004454 (UMLS CUI [3,2])
C1516728 (UMLS CUI [3,3])
Autologous hematopoietic stem cell transplant Completion
Item
completion of autologous stem cell transplant within 100 days prior study start
boolean
C2193200 (UMLS CUI [1,1])
C0205197 (UMLS CUI [1,2])
Allogeneic Stem Cell Transplantation
Item
prior allogeneic stem cell transplant
boolean
C2242529 (UMLS CUI [1])
Patients Eligible Autologous hematopoietic stem cell transplant | Diffuse large B-cell lymphoma recurrent | Diffuse large B-cell lymphoma refractory
Item
eligibility for autologous sct (patients with relapsed or refractory dlbcl)
boolean
C0030705 (UMLS CUI [1,1])
C1548635 (UMLS CUI [1,2])
C2193200 (UMLS CUI [1,3])
C0855111 (UMLS CUI [2])
C0855112 (UMLS CUI [3])
Allergic Reaction Severe Monoclonal Antibody Therapy | Anaphylaxis Severe Monoclonal Antibody Therapy | Allergic Reaction Recombinant Fusion Proteins Antibody Related | Anaphylaxis Recombinant Fusion Proteins Antibody Related
Item
history of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins)
boolean
C1527304 (UMLS CUI [1,1])
C0205082 (UMLS CUI [1,2])
C0279694 (UMLS CUI [1,3])
C0002792 (UMLS CUI [2,1])
C0205082 (UMLS CUI [2,2])
C0279694 (UMLS CUI [2,3])
C1527304 (UMLS CUI [3,1])
C0034857 (UMLS CUI [3,2])
C0003241 (UMLS CUI [3,3])
C0439849 (UMLS CUI [3,4])
C0002792 (UMLS CUI [4,1])
C0034857 (UMLS CUI [4,2])
C0003241 (UMLS CUI [4,3])
C0439849 (UMLS CUI [4,4])
Cancer Other Affecting Protocol Compliance | Cancer Other Affecting Interpretation Research results
Item
history of other malignancy that could affect compliance with the protocol or interpretation of results
boolean
C1707251 (UMLS CUI [1,1])
C0392760 (UMLS CUI [1,2])
C0525058 (UMLS CUI [1,3])
C1707251 (UMLS CUI [2,1])
C0392760 (UMLS CUI [2,2])
C0459471 (UMLS CUI [2,3])
C0683954 (UMLS CUI [2,4])
Primary central nervous system lymphoma
Item
current or past history of cns lymphoma
boolean
C0280803 (UMLS CUI [1])
Peripheral Neuropathy CTCAE Grades
Item
current grade > 1 peripheral neuropathy
boolean
C0031117 (UMLS CUI [1,1])
C1516728 (UMLS CUI [1,2])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial